CN106729640A - 一种治疗痛经的药物 - Google Patents

一种治疗痛经的药物 Download PDF

Info

Publication number
CN106729640A
CN106729640A CN201611209409.XA CN201611209409A CN106729640A CN 106729640 A CN106729640 A CN 106729640A CN 201611209409 A CN201611209409 A CN 201611209409A CN 106729640 A CN106729640 A CN 106729640A
Authority
CN
China
Prior art keywords
parts
medicine
vitamin
dysmenorrhoea
gains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611209409.XA
Other languages
English (en)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Lidiya Medicine Technology Co Ltd
Original Assignee
Zhengzhou Lidiya Medicine Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Lidiya Medicine Technology Co Ltd filed Critical Zhengzhou Lidiya Medicine Technology Co Ltd
Priority to CN201611209409.XA priority Critical patent/CN106729640A/zh
Publication of CN106729640A publication Critical patent/CN106729640A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚2‑5份、舒必利2‑5份、阿托品0.1‑2份、EGCG 0.8‑5份、亚油酸1‑5份、氯氮0.1‑1份、木糖醇5‑10份、盐酸氯丙嗪2‑5份、维生素p 0.2‑1份、α‑乳白蛋白粉1‑5份、阿胶5‑9份、双氯芬酸钠1‑5份、维生素E 2‑8份、糖皮质激素类药物2‑5份、生理盐水80‑150份。该治疗痛经的药物通过原料复配发挥协同作用，能有效治疗月经期间的腹痛、腰肢酸软、手脚发凉等症状，而且制作简单，生产成本低；该药物能彻底根治痛经，且不会使患者产生药物依赖性，副作用小，无并发症产生。

Description

一种治疗痛经的药物
技术领域
本发明涉及西药技术领域，具体是一种治疗痛经的药物。
背景技术
痛经为最常见的妇科症状之一，指行经前后或月经期出现下腹部疼痛、坠胀，伴有腰酸或其他不适，症状严重影响生活质量者。痛经分为原发性痛经和继发性两类，原发性痛经指生殖器官无器质性病变的痛经，占痛经90％以上；继发性痛经指由盆腔器质性疾病引起的痛经。
痛经的病因有：1)原发性痛经的发生主要与月经时子宫内膜前列腺素含量增高有关，PGF2α含量升高时造成痛经的主要原因，PGF2α含量高可引起子宫平滑肌过强收缩，血管痉挛，造成子宫缺血、乏氧状态而出现痛经；2)血管加压素、内源性缩宫素以及β-内啡肽等物质的增加；3)精神、神经因素。
临床表现有：疼痛多自月经来潮后开始，最早出现在经前12小时，以行经第1日疼痛最剧烈，持续2～3日后缓解。疼痛常呈痉挛性，位于下腹部耻骨上，可放射至腰骶部和大腿内侧；可伴有恶心、呕吐、腹泻、头晕、乏力等症状，严重时面色发白、出冷汗。
目前，痛经的治疗方法主要有精神疏导、中药、西药与针灸治疗。但是现有的治疗痛经的中药存在疗效长、见效慢、口感差的缺点，患者很难坚持；而现有的西药虽然见效快，疗效短，但是不能彻底根治，且会使患者产生一定的药物依赖性，很多患者还出现了副作用和并发症，严重危害了患者的身体健康。
发明内容
本发明的目的在于提供一种治疗痛经的药物，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚2-5份、舒必利2-5份、阿托品0.1-2份、EGCG 0.8-5份、亚油酸1-5份、氯氮0.1-1份、木糖醇5-10份、盐酸氯丙嗪2-5份、维生素p 0.2-1份、α-乳白蛋白粉1-5份、阿胶5-9份、双氯芬酸钠1-5份、维生素E2-8份、糖皮质激素类药物2-5份、生理盐水80-150份。
作为本发明进一步的方案：由以下重量份数的原料组成：对乙酰氨基酚4份、舒必利3份、阿托品0.5份、EGCG 2份、亚油酸3份、氯氮0.2份、木糖醇6份、盐酸氯丙嗪4份、维生素p 0.5份、α-乳白蛋白粉3份、阿胶8份、双氯芬酸钠4份、维生素E 6份、糖皮质激素类药物4份、生理盐水105份。
作为本发明再进一步的方案：所述糖皮质激素类药为复方倍他米松、氢化可的松或氟轻松。
一种治疗痛经的药物的制备方法，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、EGCG、亚油酸、氯氮、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛80-120目；
(3)将阿胶与70-90℃温度的生理盐水混合，通过搅拌机搅拌混合20-45min；
(4)将EGCG、氯氮与步骤(3)所得物在常温下混合搅拌20-50min，并用超声波震荡10-20min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌10-30min，并用超声波震荡10-30min；
(7)将上步所得物在70-90℃温度下干燥25-40min，即得成品。
作为本发明再进一步的方案：所述步骤(3)将阿胶与80℃温度的生理盐水混合，通过搅拌机搅拌混合25min。
作为本发明再进一步的方案：所述步骤(6)将步骤(5)所得物与步骤(6)所得物混合搅拌18min，并用超声波震荡15min。
与现有技术相比，本发明的有益效果是：
该治疗痛经的药物通过原料复配发挥协同作用，不仅可满足治疗痛经的迫切需求，显著提高临床疗效，而且能使病人降低医疗成本，减少医疗费用，具有良好的经济效益和社会效益；该药物能有效治疗月经期间的腹痛、腰肢酸软、手脚发凉等症状，而且制作简单，生产成本低；该药物能彻底根治痛经，且不会使患者产生药物依赖性，副作用小，无并发症产生，是一种安全有效的药物。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚2份、舒必利2份、阿托品0.1份、EGCG 0.8份、亚油酸1份、氯氮0.1份、木糖醇5份、盐酸氯丙嗪2份、维生素p0.2份、α-乳白蛋白粉1份、阿胶5份、双氯芬酸钠1份、维生素E 2份、糖皮质激素类药物2份、生理盐水80份。
所述糖皮质激素类药为复方倍他米松。
一种治疗痛经的药物的制备方法，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、EGCG、亚油酸、氯氮、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛80目；
(3)将阿胶与70℃温度的生理盐水混合，通过搅拌机搅拌混合20min；
(4)将EGCG、氯氮与步骤(3)所得物在常温下混合搅拌20min，并用超声波震荡10min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌10min，并用超声波震荡10min；
(7)将上步所得物在70℃温度下干燥25min，即得成品。
实施例2
一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚5份、舒必利5份、阿托品2份、EGCG 5份、亚油酸5份、氯氮1份、木糖醇10份、盐酸氯丙嗪5份、维生素p 1份、α-乳白蛋白粉5份、阿胶9份、双氯芬酸钠5份、维生素E 8份、糖皮质激素类药物5份、生理盐水150份。
所述糖皮质激素类药为氢化可的松。
一种治疗痛经的药物的制备方法，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、EGCG、亚油酸、氯氮、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛120目；
(3)将阿胶与90℃温度的生理盐水混合，通过搅拌机搅拌混合45min；
(4)将EGCG、氯氮与步骤(3)所得物在常温下混合搅拌50min，并用超声波震荡20min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌30min，并用超声波震荡30min；
(7)将上步所得物在90℃温度下干燥40min，即得成品。
实施例3
一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚4份、舒必利3份、阿托品0.5份、EGCG 2份、亚油酸3份、氯氮0.2份、木糖醇6份、盐酸氯丙嗪4份、维生素p0.5份、α-乳白蛋白粉3份、阿胶8份、双氯芬酸钠4份、维生素E 6份、糖皮质激素类药物4份、生理盐水105份。
所述糖皮质激素类药为氟轻松。
一种治疗痛经的药物的制备方法，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、EGCG、亚油酸、氯氮、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛100目；
(3)将阿胶与80℃温度的生理盐水混合，通过搅拌机搅拌混合25min；
(4)将EGCG、氯氮与步骤(3)所得物在常温下混合搅拌35min，并用超声波震荡16min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌18min，并用超声波震荡15min；
(7)将上步所得物在75℃温度下干燥30min，即得成品。
对比例1
一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚4份、舒必利3份、阿托品0.5份、亚油酸3份、氯氮0.2份、木糖醇6份、盐酸氯丙嗪4份、维生素p 0.5份、α-乳白蛋白粉3份、阿胶8份、双氯芬酸钠4份、维生素E 6份、糖皮质激素类药物4份、生理盐水105份。
所述糖皮质激素类药为氟轻松。
一种治疗痛经的药物的制备方法，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、亚油酸、氯氮、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛100目；
(3)将阿胶与80℃温度的生理盐水混合，通过搅拌机搅拌混合25min；
(4)将氯氮与步骤(3)所得物在常温下混合搅拌35min，并用超声波震荡16min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌18min，并用超声波震荡15min；
(7)将上步所得物在75℃温度下干燥30min，即得成品。
对比例1中未添加EGCG。
对比例2
一种治疗痛经的药物，由以下重量份数的原料组成：对乙酰氨基酚4份、舒必利3份、阿托品0.5份、EGCG 2份、亚油酸3份、木糖醇6份、盐酸氯丙嗪4份、维生素p 0.5份、α-乳白蛋白粉3份、阿胶8份、双氯芬酸钠4份、维生素E 6份、糖皮质激素类药物4份、生理盐水105份。
所述糖皮质激素类药为氟轻松。
一种治疗痛经的药物的制备方法，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、EGCG、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛100目；
(3)将阿胶与80℃温度的生理盐水混合，通过搅拌机搅拌混合25min；
(4)将EGCG与步骤(3)所得物在常温下混合搅拌35min，并用超声波震荡16min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌18min，并用超声波震荡15min；
(7)将上步所得物在75℃温度下干燥30min，即得成品。
对比例2中未添加氯氮。
试验例
选择300例痛经患者，年龄15-55岁，痛经史1-30年。
将300例患者随机分为三组，每组100例，即治疗组、对照1组、对照2组。治疗组在经期前1周开始每日服用实施例3制备的药物，对照1组在经期前1周开始每日服用对比例1制备的药物，对照2组在经期前1周开始每日服用对比例2制备的药物，每次服用0.5g，每天服用1次，一周为一个疗程。
疗效评定标准
显效：服用三个疗程，痛经症状消失，半年内无复发。
有效：服用三个疗程，痛经症状明显减轻，坚持服用五个疗程，痛经症状彻底消失，半年内无复发。
无效：服用两个疗程后，痛经症状无改变，或半年内复发。
显效加有效为有效例数，并计算有效率。
治疗结果见下表：
项目 例数/例 显效/例 有效/例 无效/例 有效率/％
实施例3 100 68 31 1 99
对比例1 100 20 35 45 55
对比例2 100 15 35 50 50
由上表可以看出，氯氮和EGCG可以有效提高该药物的疗效。综合有效率达99％。
该治疗痛经的药物通过原料复配发挥协同作用，不仅可满足治疗痛经的迫切需求，显著提高临床疗效，而且能使病人降低医疗成本，减少医疗费用，具有良好的经济效益和社会效益；该药物能有效治疗月经期间的腹痛、腰肢酸软、手脚发凉等症状，而且制作简单，生产成本低；该药物能彻底根治痛经，且不会使患者产生药物依赖性，副作用小，无并发症产生，是一种安全有效的药物。
上面对本专利的较佳实施方式作了详细说明，但是本专利并不限于上述实施方式，在本领域的普通技术人员所具备的知识范围内，还可以在不脱离本专利宗旨的前提下做出各种变化。

Claims (6)

1.一种治疗痛经的药物，其特征在于，由以下重量份数的原料组成：对乙酰氨基酚2-5份、舒必利2-5份、阿托品0.1-2份、EGCG 0.8-5份、亚油酸1-5份、氯氮0.1-1份、木糖醇5-10份、盐酸氯丙嗪2-5份、维生素p 0.2-1份、α-乳白蛋白粉1-5份、阿胶5-9份、双氯芬酸钠1-5份、维生素E 2-8份、糖皮质激素类药物2-5份、生理盐水80-150份。
2.根据权利要求1所述的治疗痛经的药物，其特征在于，由以下重量份数的原料组成：对乙酰氨基酚4份、舒必利3份、阿托品0.5份、EGCG 2份、亚油酸3份、氯氮0.2份、木糖醇6份、盐酸氯丙嗪4份、维生素p 0.5份、α-乳白蛋白粉3份、阿胶8份、双氯芬酸钠4份、维生素E 6份、糖皮质激素类药物4份、生理盐水105份。
3.根据权利要求1-2任一所述的治疗痛经的药物，其特征在于，所述糖皮质激素类药为复方倍他米松、氢化可的松或氟轻松。
4.一种如权利要求1-2任一所述的治疗痛经的药物的制备方法，其特征在于，具体步骤为：
(1)称取各原料，备用；
(2)碾碎：将对乙酰氨基酚、舒必利、阿托品、EGCG、亚油酸、氯氮、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物分别碾碎成粉末，并过筛80-120目；
(3)将阿胶与70-90℃温度的生理盐水混合，通过搅拌机搅拌混合20-45min；
(4)将EGCG、氯氮与步骤(3)所得物在常温下混合搅拌20-50min，并用超声波震荡10-20min；
(5)对乙酰氨基酚、舒必利、阿托品、亚油酸、木糖醇、盐酸氯丙嗪、维生素p、α-乳白蛋白粉、双氯芬酸钠、维生素E、糖皮质激素类药物混合均匀；
(6)将步骤(5)所得物与步骤(6)所得物混合搅拌10-30min，并用超声波震荡10-30min；
(7)将上步所得物在70-90℃温度下干燥25-40min，即得成品。
5.根据权利要求4所述的治疗痛经的药物的制备方法，其特征在于，所述步骤(3)将阿胶与80℃温度的生理盐水混合，通过搅拌机搅拌混合25min。
6.根据权利要求4所述的治疗痛经的药物的制备方法，其特征在于，所述步骤(6)将步骤(5)所得物与步骤(6)所得物混合搅拌18min，并用超声波震荡15min。
CN201611209409.XA 2016-12-23 2016-12-23 一种治疗痛经的药物 Withdrawn CN106729640A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611209409.XA CN106729640A (zh) 2016-12-23 2016-12-23 一种治疗痛经的药物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611209409.XA CN106729640A (zh) 2016-12-23 2016-12-23 一种治疗痛经的药物

Publications (1)

Publication Number Publication Date
CN106729640A true CN106729640A (zh) 2017-05-31

Family

ID=58919358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611209409.XA Withdrawn CN106729640A (zh) 2016-12-23 2016-12-23 一种治疗痛经的药物

Country Status (1)

Country Link
CN (1) CN106729640A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103251900A (zh) * 2013-04-22 2013-08-21 山东大学齐鲁医院 一种治疗痛经的药物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103251900A (zh) * 2013-04-22 2013-08-21 山东大学齐鲁医院 一种治疗痛经的药物

Similar Documents

Publication Publication Date Title
Lockwood Maximizing aesthetics in lateral-tension abdominoplasty and body lifts
Caton et al. Anesthesia for childbirth: controversy and change
Brent Addison's disease and pregnancy
Johnstone et al. Endocrine system: part 1
CN102078391A (zh) 一种治疗颈肩腰腿疼痛的药物
Scheinberg et al. Sciatic neuropathy in infants related to antibiotic injections
CN106729640A (zh) 一种治疗痛经的药物
CN106729602A (zh) 一种治疗痛经的药物组合物
CN106729604A (zh) 一种治疗痛经的药物
CN106581648A (zh) 一种治疗月经失调的药物
CN104623498B (zh) 一种孕妇安胎的中药组合物
CN102406898B (zh) 一种治疗牛皮癣的药物及其制备方法
CN108379384A (zh) 一种补肾中药组合物及其制备方法
CN100400049C (zh) 治疗脚气病药粉
CN106420976A (zh) 一种治疗腰椎间盘突出的膏药及其制作方法
Golden Lesions of ischium and pubis in pregnancy resembling osteitis
CN106420908A (zh) 一种治疗白发的西药复方制剂
Chen et al. Nursing Care of a Patient with Cervical Spinal Cord Injury Without Fracture and Dislocation: A Case Report
Paxson Obstetrical Anesthesia and Analgesia With Sodium Iso-amyl Ethyl Barbiturate and Nitrous Oxid-Oxygen: Results in Obstetrical Practice.
Daher et al. Torsoplasty Improving Body Contouring
Chaney et al. Groin Injury-Football: 2123 June 1 9: 50 AM-10: 10 AM
CN104857111B (zh) 治疗腰椎间盘突出症引起的腰腿痛的药剂及其制备方法
Pearson Addison's Disease in a 6-year-old Boy
CN109512841A (zh) 一种用于治疗痔疮的药物及其制备方法
CN109453230A (zh) 一种治疗疥疮结节的药膏及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531

WW01 Invention patent application withdrawn after publication